Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …

In the last 4 years, several evidence-based, national, and international guidelines on the
management of arterial hypertension have been published, mostly with concordant …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Hypertension is the most important modifiable cause of cardiovascular (CV) disease and all-
cause mortality worldwide. Despite the positive correlations between blood pressure (BP) …

Renal denervation is a promising new non-pharmacological treatment for resistant
hypertension. However, there is a lack of data from Asian patients. The REQUIRE trial …

The clinical and economic burden of hypertension is high and continues to increase
globally. Uncontrolled hypertension has severe but avoidable long‐term consequences …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

The efficacy of renal denervation has been controversial, but recent randomized sham-
controlled trials demonstrated significant blood pressure reductions after renal denervation …

Renal denervation is a potential alternative to antihypertensive drug therapy. However, data
on patient preference for this treatment option are limited and there are no data specifically …

Aims Renal denervation has been shown to lower blood pressure in sham-controlled trials
and represents a device-based treatment option for hypertension. We sought to project …